Topics such as “Genetics”, “Pathology”, “Oligometastatic disease”, “Ductal carcinoma in situ” and “Well-being for breast cancer survivors” showed very high agreement, while the model’s performance was less satisfactory in areas like “BRCA associated”, “Adjuvant endocrine therapy”, “HER2 positive”, “Local/regional recurrence” and “Bone-modifying therapy”. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.